187 related articles for article (PubMed ID: 37314501)
21. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.
Jankowitz RC; Abraham J; Tan AR; Limentani SA; Tierno MB; Adamson LM; Buyse M; Wolmark N; Jacobs SA
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1205-12. PubMed ID: 24077916
[TBL] [Abstract][Full Text] [Related]
22. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Bedard PL; Tabernero J; Janku F; Wainberg ZA; Paz-Ares L; Vansteenkiste J; Van Cutsem E; Pérez-García J; Stathis A; Britten CD; Le N; Carter K; Demanse D; Csonka D; Peters M; Zubel A; Nauwelaerts H; Sessa C
Clin Cancer Res; 2015 Feb; 21(4):730-8. PubMed ID: 25500057
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM; van Brummelen EMJ; Eskens FALM; Huijberts SCFA; de Vos FYFL; Lolkema MPJK; Devriese LA; Opdam FL; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Br J Cancer; 2020 Apr; 122(8):1166-1174. PubMed ID: 32147669
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.
Spicer J; Baird R; Suder A; Cresti N; Corbacho JG; Hogarth L; Frenkel E; Matsumoto S; Kawabata I; Donaldson K; Posner J; Sarker D; Jodrell D; Plummer R
Eur J Cancer; 2015 Jan; 51(2):137-45. PubMed ID: 25434923
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
Abraham J; Montero AJ; Jankowitz RC; Salkeni MA; Beumer JH; Kiesel BF; Piette F; Adamson LM; Nagy RJ; Lanman RB; Sperinde J; Huang W; Allegra CJ; Srinivasan A; Wang Y; Pogue-Geile KL; Lucas PC; Jacobs SA
J Clin Oncol; 2019 Oct; 37(29):2601-2609. PubMed ID: 31442103
[TBL] [Abstract][Full Text] [Related]
26. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Borthakur G; Popplewell L; Boyiadzis M; Foran J; Platzbecker U; Vey N; Walter RB; Olin R; Raza A; Giagounidis A; Al-Kali A; Jabbour E; Kadia T; Garcia-Manero G; Bauman JW; Wu Y; Liu Y; Schramek D; Cox DS; Wissel P; Kantarjian H
Cancer; 2016 Jun; 122(12):1871-9. PubMed ID: 26990290
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.
Awada A; Dirix L; Manso Sanchez L; Xu B; Luu T; Diéras V; Hershman DL; Agrapart V; Ananthakrishnan R; Staroslawska E
Ann Oncol; 2013 Jan; 24(1):109-16. PubMed ID: 22967996
[TBL] [Abstract][Full Text] [Related]
29. Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study.
Ito Y; Suenaga M; Hatake K; Takahashi S; Yokoyama M; Onozawa Y; Yamazaki K; Hironaka S; Hashigami K; Hasegawa H; Takenaka N; Boku N
Jpn J Clin Oncol; 2012 Apr; 42(4):278-86. PubMed ID: 22371427
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Corcoran RB; Do KT; Kim JE; Cleary JM; Parikh AR; Yeku OO; Xiong N; Weekes CD; Veneris J; Ahronian LG; Mauri G; Tian J; Norden BL; Michel AG; Van Seventer EE; Siravegna G; Camphausen K; Chi G; Fetter IJ; Brugge JS; Chen H; Takebe N; Penson RT; Juric D; Flaherty KT; Sullivan RJ; Clark JW; Heist RS; Matulonis UA; Liu JF; Shapiro GI
Clin Cancer Res; 2024 May; 30(9):1739-1749. PubMed ID: 38456660
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
[TBL] [Abstract][Full Text] [Related]
33. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
34. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer.
Zhang T; Li Q; Chen S; Luo Y; Fan Y; Xu B
Oncotarget; 2017 May; 8(22):36750-36760. PubMed ID: 27902470
[TBL] [Abstract][Full Text] [Related]
37. A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer.
Chuang J; Gong J; Li SM; Wang C; Fakih M
Clin Colorectal Cancer; 2022 Sep; 21(3):252-258. PubMed ID: 35738999
[TBL] [Abstract][Full Text] [Related]
38. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
39. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
40. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
